Although more research is needed, the initial findings are promising and point to a new potential use for these medications
Patient experiences depend on personal health factors, adherence to the program, and provider recommendations
Managing Side Effects Most side effects occur during the first few months of treatment and during dose increases
1 In a study of 3,297 patients with established cardiovascular disease already on standard treatment, the addition of semaglutide reduced the composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke by 2.3 percentage points as compared with placebo (6.6% vs
Counsel patients regarding the potential risk for MTC with the use of RYBELSUS or OZEMPIC tablets and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness)